The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection
T.-F. Tsai,1 V. Ho,2 M. Song,3 P. Szapary,3 T. Kato,4 Y. Wasfi,3 S. Li,5 Y.K. Shen,5 and C. Leonardi6 on behalf of
the PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups
1Department of Dermatology, National Taiwan University Hospital, 7 Chung-Shan S. Road, Taipei, Taiwan
2Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada
Departments of 3Immunology and 5Biostatistics Janssen Research & Development, LLC, Spring House, PA, U.S.A.
4Division of Clinical Science, Janssen Pharmaceutical K.K., Tokyo, Japan
6Department of Dermatology, St Louis University, St Louis, MO, U.S.A.

Fuente: British Journal of Dermatology 2012 167, pp1145–1152